Literature DB >> 20803281

[Geriatrics and radiation oncology. Part 1: How to identify high-risk patients and basic treatment principles].

Franziska Fels1, Johannes W Kraft, Gerhard G Grabenbauer.   

Abstract

BACKGROUND: Until the mid of this century, 33% of the Western population will be > or = 65 years old. The percentage of patients being > or = 80 years old with today 5% will triple until 2050. Therefore, radiation oncologists must be familiar with special geriatric issues to meet the increasing demand for multidisciplinary cooperation and to offer useful and individual treatment concepts. PATIENTS AND METHODS: This review article will provide basic data on the definition, identification and treatment of geriatric cancer patients.
RESULTS: The geriatric patient is defined by typical multimorbidity (15 items) and by age-related increased vulnerability. Best initial identification of geriatric patients will be provided by assessment including the Barthel Index evaluating self-care and activity in daily life, by the Mini-Mental Status Test that will address cognitive pattern, and by the Timed "Up&Go" Test for evaluation of mobility. As for chemotherapy, standard treatment was associated with increased toxicity, consequently, dose modifications and supportive treatment are of special importance.
CONCLUSION: Geriatric cancer patients need to be identified by special assessment instruments. Due to increased toxicity following chemotherapy, supportive measures seem important. Radiation treatment as a noninvasive and outpatient-based treatment remains an important and preferable option.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20803281     DOI: 10.1007/s00066-010-2045-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  23 in total

1.  Implantable cardiac defibrillators may be damaged by radiation therapy.

Authors:  S Hoecht; P Rosenthal; D Sancar; S Behrens; W Hinkelbein; U Hoeller
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

2.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

3.  FUNCTIONAL EVALUATION: THE BARTHEL INDEX.

Authors:  F I MAHONEY; D W BARTHEL
Journal:  Md State Med J       Date:  1965-02

4.  Incidence, therapy and prognosis of colorectal cancer in different age groups. A population-based cohort study of the Rostock Cancer Registry.

Authors:  Rainer Fietkau; Heike Zettl; Sabine Klöcking; Günther Kundt
Journal:  Strahlenther Onkol       Date:  2004-08       Impact factor: 3.621

5.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

6.  Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study.

Authors:  G Freyer; J-F Geay; S Touzet; J Provencal; B Weber; J-P Jacquin; G Ganem; N Tubiana-Mathieu; O Gisserot; E Pujade-Lauraine
Journal:  Ann Oncol       Date:  2005-08-10       Impact factor: 32.976

7.  [Social aspects in diagnosis and therapy of very elderly patients. Initial experiences with a newly developed questionnaire within the scope of geriatric assessment].

Authors:  T Nikolaus; N Specht-Leible; M Bach; P Oster; G Schlierf
Journal:  Z Gerontol       Date:  1994 Jul-Aug

8.  Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients.

Authors:  T Mahoney; Y H Kuo; A Topilow; J M Davis
Journal:  Arch Surg       Date:  2000-02

9.  Management of cancer in the older person: a practical approach.

Authors:  L Balducci; M Extermann
Journal:  Oncologist       Date:  2000

10.  Polypharmacy and inappropriate prescribing in elderly internal-medicine patients in Austria.

Authors:  Jochen Schuler; Christina Dückelmann; Wolfgang Beindl; Erika Prinz; Thomas Michalski; Max Pichler
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

View more
  6 in total

1.  Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. Treatment outcome outside clinical trials.

Authors:  J Winkler; L Zipp; J Knoblich; F Zimmermann
Journal:  Strahlenther Onkol       Date:  2012-03-10       Impact factor: 3.621

2.  Japanese structure survey of radiation oncology in 2007 with special reference to designated cancer care hospitals.

Authors:  Hodaka Numasaki; Hitoshi Shibuya; Masamichi Nishio; Hiroshi Ikeda; Kenji Sekiguchi; Norihiko Kamikonya; Masahiko Koizumi; Masao Tago; Yutaka Ando; Nobuhiro Tsukamoto; Atsuro Terahara; Katsumasa Nakamura; Michihide Mitsumori; Tetsuo Nishimura; Masato Hareyama; Teruki Teshima
Journal:  Strahlenther Onkol       Date:  2011-02-21       Impact factor: 3.621

3.  [Survey of potential improvements during the course of the radiotherapy treatment--a patient questionnaire].

Authors:  Felix Momm; David Jooss; Carola J Xander; Sonja Adebahr; Viola Duncker-Rohr; Felix Heinemann; Simon Kirste; Marc-Benjamin Messmer; Anca-Ligia Grosu; Gerhild Becker
Journal:  Strahlenther Onkol       Date:  2011-10-28       Impact factor: 3.621

4.  Time management in radiation oncology: development and evaluation of a modular system based on the example of rectal cancer treatment. The DEGRO-QUIRO trial.

Authors:  R Fietkau; W Budach; N Zamboglou; H-J Thiel; H Sack; W Popp
Journal:  Strahlenther Onkol       Date:  2011-12-24       Impact factor: 3.621

5.  Radiotherapy with and without temozolomide in elderly patients with glioblastoma.

Authors:  M Niyazi; S B Schwarz; B Suchorska; C Belka
Journal:  Strahlenther Onkol       Date:  2012-01-11       Impact factor: 3.621

6.  Impact of intensity-modulated and image-guided radiotherapy on elderly patients undergoing chemoradiation for locally advanced head and neck cancer.

Authors:  N P Nguyen; J Vock; A Chi; V Vinh-Hung; S Dutta; L Ewell; S Jang; M Betz; F Almeida; M Miller; R Davis; T Sroka; R P Vo; U Karlsson; P Vos
Journal:  Strahlenther Onkol       Date:  2012-06-03       Impact factor: 3.621

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.